Pieris Pharmaceuticals Partner AstraZeneca Discontinue P-IIa Clinical Trial of Elarekibep (PRS-060/AZD1402) for the Treatment of Asthma
Shots:
- Pieris highlighted that its partner AstraZeneca has decided to stop dosing & discontinue the P-IIa trial evaluating elarekibep, an inhaled IL-4 receptor alpha inhibitor for the treatment of asthma
- The decision was based on a non-clinical 13wk. GLP toxicology study for the dry powder inhaler-formulated elarekibep which revealed inflammation-related lung tissue damage
- Pieris will expedite a review of the implications of the data. Additionally, the favorable longer-term non-clinical data would be essential to support later-stage advancement of the ongoing P-IIa study of elarekibep
Ref: Pieris Pharmaceuticals | Image: Pieris Pharmaceuticals
Related News:- Pieris Out-licenses PRS-342 to Boston Pharmaceuticals for ~$363M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
